The burning hole in Gilead's $25B pocket and AbbVie's future in hematology

FierceBiotech Radio

Fierce editors discuss the discussion around Gilead Sciences' huge cash reserve and the many things the company might buy. Plus, a look back at AbbVie's blockbuster buyout of Pharmacyclics and a thoughtful consideration...View more